Overview

Safety and Efficacy of Genakumab for Injection in Patients With Gout Flare

Status:
COMPLETED
Trial end date:
2024-02-28
Target enrollment:
Participant gender:
Summary
To evaluate the safety and efficacy of Genakumab for Injection in patients with gout flare as a first line therapy
Phase:
PHASE2
Details
Lead Sponsor:
Changchun GeneScience Pharmaceutical Co., Ltd.
Collaborator:
Huashan Hospital
Treatments:
Colchicine
Injections